Vita 34 AG
XETRA:V3V
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.96
5.38
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one V3V stock under the Base Case scenario is 3.6 EUR. Compared to the current market price of 4.16 EUR, Vita 34 AG is Overvalued by 13%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Vita 34 AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for V3V cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Vita 34 AG
Balance Sheet Decomposition
Vita 34 AG
Current Assets | 37.9m |
Cash & Short-Term Investments | 16.1m |
Receivables | 16.3m |
Other Current Assets | 5.5m |
Non-Current Assets | 119.7m |
Long-Term Investments | 1.5m |
PP&E | 37m |
Intangibles | 55.4m |
Other Non-Current Assets | 25.7m |
Current Liabilities | 53.1m |
Accounts Payable | 7.2m |
Other Current Liabilities | 45.9m |
Non-Current Liabilities | 81.5m |
Long-Term Debt | 12.7m |
Other Non-Current Liabilities | 68.7m |
Earnings Waterfall
Vita 34 AG
Revenue
|
78.8m
EUR
|
Cost of Revenue
|
-48.9m
EUR
|
Gross Profit
|
29.9m
EUR
|
Operating Expenses
|
-32m
EUR
|
Operating Income
|
-2.1m
EUR
|
Other Expenses
|
2m
EUR
|
Net Income
|
-127k
EUR
|
Free Cash Flow Analysis
Vita 34 AG
EUR | |
Free Cash Flow | EUR |
V3V Profitability Score
Profitability Due Diligence
Vita 34 AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Vita 34 AG's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
V3V Solvency Score
Solvency Due Diligence
Vita 34 AG's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Vita 34 AG's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
V3V Price Targets Summary
Vita 34 AG
According to Wall Street analysts, the average 1-year price target for V3V is 6.43 EUR with a low forecast of 6.36 EUR and a high forecast of 6.62 EUR.
Dividends
Current shareholder yield for V3V is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
V3V Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
Contact
IPO
Employees
Officers
The intrinsic value of one V3V stock under the Base Case scenario is 3.6 EUR.
Compared to the current market price of 4.16 EUR, Vita 34 AG is Overvalued by 13%.